Search

everythinglearnresearchcommunity

for

Search:↓

A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.

A new compound, 3a, effectively fights prostate cancer better than finasteride.

A new method creates unique chemical structures that could improve drug discovery.

New pyridine compounds effectively inhibit GSK3, a diabetes treatment target.

Piperonylic acid may help hair growth and treat hair loss.

Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.

Finasteride doesn't affect antipyrine metabolism, so interactions with cytochrome P-450 enzyme drugs are unlikely.

Trienones are more effective at inhibiting the enzyme linked to hair loss than dienones.

PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.

The compound was successfully made and shows potential for treating prostate cancer.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Topical putrescine and spermine increased DNA synthesis in hairless mouse skin.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

New molecules can prevent cell death in hair follicles.

The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.

PXX is an effective and affordable photocatalyst for creating new chemical bonds in organic synthesis.

A new antiandrogen compound was made and its detailed three-dimensional shape was described.

A new compound with strong antiandrogenic effects was found, potentially useful for treating conditions like acne and prostate cancer.

The new palladium catalyst is effective and reusable for making pharmaceutical ingredients.

N13-substituted evodiamine derivatives improved anticancer activity and solubility, showing promise for drug development.

Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.

Compound 15a was effective in inhibiting 5α-reductase.

The NUDT15 R139C variant causes thiopurine-induced leukocytopenia through a different mechanism than previously thought in Japanese patients with inflammatory bowel disease.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.